RJA
RARX

Raymond James & Associates’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Raymond James & Associates’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,621
Closed -$545K – 3819
2019
Q4 		$545K Sell
11,621
-4,056
-26% -$179K ﹤0.01% 2666
2019
Q3 		$371K Buy
15,677
+4,587
+41% +$136K ﹤0.01% 2866
2019
Q2 		$333K Sell
11,090
-1,260
-10% -$28.9K ﹤0.01% 2942
2019
Q1 		$277K Sell
12,350
-3,570
-22% -$76.8K ﹤0.01% 3026
2018
Q4 		$290K Buy
+15,920
New +$250K ﹤0.01% 2892

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James & Associates's RARX Position: Q1 2020 in Review

Raymond James & Associates sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q1 2020, closing a stake of 11,621 shares — an estimated $545K sold.

Raymond James & Associates first reported a position in RARX in Q4 2018 and held it in 5 quarters. The position peaked at $545K in Q4 2019. 144 funds tracked by Wall St. Rank hold RARX as of Q1 2020.

  • Raymond James & Associates reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Raymond James & Associates sold 11,621 Ra Pharmaceuticals, Inc. Common Stock shares in Q1 2020, an estimated $545K.
  • Raymond James & Associates first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
  • Raymond James & Associates's Ra Pharmaceuticals, Inc. Common Stock position peaked at $545K in Q4 2019.
  • 144 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q1 2020.

Based on Raymond James & Associates's 13F filing for Q1 2020, filed 21 Apr 2020.